Skip Nav Destination
Issues
1 June 2020
-
Cover Image
Cover Image
Green tea is a popular beverage in East Asia that is gaining popularity as a health-promoting natural product in the Western world. It is a rich source of natural polyphenols, among which epigallocatechin gallate (EGCG) is the most abundant. In this issue, Sojoodi et al. investigated the impact of EGCG on hepatocellular carcinoma (HCC) development and found a novel mechanism of EGCG-mediated chemoprevention (see the study beginning on page 497). Chronic liver injury leads to fibrosis, which can progress to cirrhosis — a major risk factor for HCC. Fibrosis results from the transdifferentiation of hepatic stellate cells (HSCs) into myofibroblasts, which deposit extracellular matrix and recruit immune cells to sites of injury. In cell culture and animal models, EGCG promoted senescence of HSCs, which in turn attenuated the progression of fibrosis to cirrhosis and ultimately prevented development of HCC. These results provide preclinical evidence that consumption of green tea or EGCG is a potentially safe and inexpensive HCC chemopreventive strategy. The image on the cover depicts immunofluorescent staining of liver tissue for α-smooth muscle actin (red) and proliferating cell nuclear antigen (green) to identify activated HSCs, which were significantly decreased in the animals receiving EGCG in their drinking water. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Editorial
Research Articles
Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma
Mozhdeh Sojoodi; Lan Wei; Derek J. Erstad; Suguru Yamada; Tsutomu Fujii; Hadassa Hirschfield; Rosa S. Kim; Gregory Y. Lauwers; Michael Lanuti; Yujin Hoshida; Kenneth K. Tanabe; Bryan C. Fuchs
External Validation of Risk Prediction Models Incorporating Common Genetic Variants for Incident Colorectal Cancer Using UK Biobank
Catherine L. Saunders; Britt Kilian; Deborah J. Thompson; Luke J. McGeoch; Simon J. Griffin; Antonis C. Antoniou; Jon D. Emery; Fiona M. Walter; Joe Dennis; Xin Yang; Juliet A. Usher-Smith
Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial
Kathleen Torkko; Cathee Till; Catherine M. Tangen; Phyllis J. Goodman; Xiaoling Song; Jeannette M. Schenk; M. Scott Lucia; Ulrike Peters; Adrie van Bokhoven; Ian M. Thompson; Marian L. Neuhouser
Impact of Social Support on Colorectal Cancer Screening among Adult Hispanics/Latinos: A Randomized Community-based Study in Central Pennsylvania
Oralia G. Dominic; Vern Chinchilli; Emily Wasserman; William J. Curry; Daniel M. Kambic; Christian H. Caicedo; Amelie G. Ramirez; John A. Ochoa; Eugene J. Lengerich
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.